Structural Racism in Medicine and Health Care – JAMA Network video discussion with Lisa A. Cooper, MD, MPH, of Johns Hopkins University School of Medicine, Clyde W. Yancy, MD, MSc, of Northwestern Medicine, and David R. Williams, PhD, MPH, of Harvard T.H. Chan School of Public Health join JAMA Editor in Chief Howard Bauchner, MD, to discuss racism and structural racism in health care and medicine. Recorded March 16, 2021
- This podcast was done is response to the controversial podcast originally posted on 24Feb which has since been deleted and remains a topic for continued discussion
- The Groundwater of Racial and Ethnic Disparities Research – 25Mar2021 Circulation: CV Quality & Outcomes – An important topic for which more attention and corrections are sorely required to achieve cardiovascular health equity for all racial and ethnic populations.
- Embracing Genetic Diversity to Improve Black Health – NEJM 25mar2021 – Akinyemi Oni-Orisan, Pharm.D., Ph.D., Yusuph Mavura, M.S., Yambazi Banda, Ph.D., Timothy A. Thornton, Ph.D., and Ronnie Sebro, M.D., Ph.D. - Complimentary download of full article from NEJM
- Incentivizing Vaccination Uptake - The “Green Pass” Proposal - As opposed to traditional incentives, the green pass allows access to social, cultural, and sports events, as well as to gyms, hotels, and restaurants for individuals who have been vaccinated (or with proven immunity) while penalizing those who have not. They will be required to show this permit to purchase tickets for events or on entry to certain venues. Published in JAMA 15Mar2021
- Combating Anti-Asian Sentiment — A Practical Guide for Clinicians – 24March2021 New New Journal of Medicine Perspective by James H. lee, MD – Complimentary download of full article from NEJM
- FDA Cracks Down on Companies Selling Unapproved CBD Products - The FDA has previously sent warning letters to other companies illegally selling unapproved CBD products that claimed to prevent, diagnose, mitigate, treat or cure various diseases, in violation of the FD&C Act. The FDA has not approved any CBD-containing drug products other than one prescription drug for the treatment of seizures associated with tuberous sclerosis complex, Lennox-Gastaut syndrome and Dravet syndrome in human patients. Products Listing CBD as Inactive Ingredient Cited for Unapproved Drug and Misbranding Violations
- Health Literacy in Healthy People 2030 - Health literacy is a central focus of Healthy People 2030. One of the initiative’s overarching goals demonstrates this focus: “Eliminate health disparities, achieve health equity, and attain health literacy to improve the health and well-being of all.”